This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of +91.67% and +6.79%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?
by Zacks Equity Research
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes TransMedics (TMDX) a New Buy Stock
by Zacks Equity Research
TransMedics (TMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.
Compared to Estimates, TransMedics (TMDX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TransMedics (TMDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 141.38% and 16.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
TransMedics (TMDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 5.56% and 10.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 7.50% and 1.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 28.07% and 0.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of -100% and 3.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about TransMedics (TMDX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Strength Seen in Paragon 28, Inc. (FNA): Can Its 8.3% Jump Turn into More Strength?
by Zacks Equity Research
Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TMDX Stock Plunges 49.2% in Three Months: What's Behind the Downfall?
by Debanjana Dey
TransMedics is navigating macroeconomic challenges amid its focus on meaningful progress across each of its growth initiatives.